Table 6 Solicited injection site and general adverse events during the 4-day post-vaccination periods in the total vaccinated cohorts
TIV | QIV | |||
|---|---|---|---|---|
% (95% CI) | % (95% CI) | |||
18–60 years | >60 years | 18–60 years | >60 years | |
N = 50 | N = 69 | N = 56 | N = 56 | |
Injection site events | ||||
Pain | 82.0 (68.6–91.4) | 26.1 (16.3–38.1) | 73.2 (59.7–84.2) | 33.9 (21.8–47.8) |
Redness | 0.0 (0.0–7.1) | 0.0 (0.0–5.2) | 1.8 (0.0–9.6) | 0.0 (0.0–6.4) |
Swelling | 4.0 (0.5–13.7) | 1.4 (0.0–7.8) | 1.8 (0.0–9.6) | 3.6 (0.4–12.3) |
General events | ||||
Chest tightness | 0.0 (0.0–7.1) | 4.3 (0.9–12.2) | 0.0 (0.0–6.4) | 3.6 (0.4–12.3) |
Chills | 4.0 (0.5–13.7) | 0.0 (0.0–5.2) | 1.8 (0.0–9.6) | 8.9 (3.0–19.6) |
Cough | 4.0 (0.5–13.7) | 0.0 (0.0–5.2) | 5.4 (1.1–14.9) | 7.1 (2.0–17.3) |
Fatigue | 30.0 (17.9–44.6) | 10.1 (4.2–19.8) | 17.9 (8.9–30.4) | 8.9 (3.0–19.6) |
Headache | 26.0 (14.6–40.3) | 8.7 (3.3–18.0) | 19.6 (10.2–32.4) | 8.9 (3.0–19.6) |
Joint pain at other location | 12.0 (4.5–24.3) | 4.3 (0.9–12.2) | 12.5 (5.2–24.1) | 5.4 (1.1–14.9) |
Muscle pain | 34.0 (21.2–48.8) | 8.7 (3.3–18.0) | 37.5 (24.9–51.5) | 10.7 (4.0–21.9) |
Red eyes | 8.0 (2.2–19.2) | 1.4 (0.0–7.8) | 5.4 (1.1–14.9) | 0.0 (0.0–6.4) |
Sore throat | 16.0 (7.2–29.1) | 2.9 (0.4–10.1) | 12.5 (5.2–24.1) | 8.9 (3.0–19.6) |
Swelling of the face | 2.0 (0.1–10.6) | 0.0 (0.0–5.2) | 0.0 (0.0–6.4) | 0.0 (0.0–6.4) |
Increased temperature | 2.0 (0.1–10.6) | 1.4 (0.0–7.8) | 0.0 (0.0–6.4) | 0.0 (0.0–6.4) |